New Two-in-One vaccine aims to shield seniors from RSV and HMPV

NCT ID NCT06556147

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This early-stage study tests a new vaccine (VXB-241) designed to protect against two viruses that cause serious lung infections in older adults: RSV and HMPV. About 144 healthy adults aged 60-83 (and some younger adults) will receive one dose of the vaccine at different strengths, with some getting a placebo or a licensed vaccine for comparison. The main goals are to check the vaccine's safety and measure the immune response it triggers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • University of the Sunshine Coast

    Morayfield, Queensland, 4506, Australia

  • University of the Sunshine Coast

    Sippy Downs, Queensland, 4556, Australia

  • University of the Sunshine Coast

    South Brisbane, Queensland, 4101, Australia

  • Veritus Research

    Bayswater, Victoria, 3153, Australia

Conditions

Explore the condition pages connected to this study.